Abstract:Background/aim: Tuberous sclerosis complex (TSC) is a multi-system syndrome caused by loss-of-function mutation in TSC1 or TSC2. Most TSC patients present with cardiac rhabdomyoma or cortical tubers during fetal life, and the symptoms are not uniform as their age. The gene products of TSC1/2 are components of the TSC protein complex and are important role in the PI3K/AKT/mTOR (PAM) signaling pathway. Based on three members of a family with variable expressivity, the purpose of this study was to clarify the clinical features of TSC in different age groups and to analyze the genetic characteristics of TSC2 gene. Methods: Clinical exome sequencing and co-segregation were used to identify a three-generation family with four affected individuals. HEK-293T cell model was constructed for subsequent experiments. Quantitative RT-PCR, western blotting, and subcellular localization were used to analyze the expression effect of TSC2 mutation. CCK-8 assay, wound healing assay, and cell cycle analysis were used to analyze the function effect of TSC2 mutation. Result: We identified a TSC family with heterozygous deletion of exon 4 in TSC2 by clinical exon sequencing. Sanger sequencing indicated that the affected individuals have 2541-bp deletion that encompassed exon 4 and adjacent introns. Deletion of exon 4 decreased the TSC2 mRNA and protein levels in HEK-293T cells, and activated the PI3K/AKT/mTOR pathway, thereby altering the cell cycle and promoting cell proliferation and migration. Conclusion: We confirmed the pathogenicity of the large deletion in TSC2 in a three- generations family.. Deletion of exon 4 of TSC2 affected cell proliferation, migration, and cell cycle via abnormal activation of the PAM pathway. This study evaluated the pathogenic effect of deletion of exon 4 of TSC2 and investigated the underlying mechanism.

Mtor-Dependent Upregulation of Xct Blocks Melanin Synthesis and Promotes Tumorigenesis

TSC1/TSC2 Inactivation Inhibits AKT Through Mtorc1-Dependent Up-Regulation of STAT3-PTEN Cascade.

mTORC1-mediated downregulation of COX2 restrains tumor growth caused by TSC2 deficiency

A large deletion in TSC2 causes tuberous sclerosis complex by dysregulating PI3K/AKT/mTOR signaling pathway

Tumors with TSC mutations are sensitive to CDK7 inhibition through NRF2 and glutathione depletion.

TSC/mTORC1 mediates mTORC2/AKT1 signaling in c-MYC-induced murine hepatocarcinogenesis via centromere protein M

Analysis of TSC1 Mutation Spectrum in Mucosal Melanoma

A Subset of Metastatic Pancreatic Ductal Adenocarcinomas Depends Quantitatively on Oncogenic Kras/Mek/Erk-Induced Hyperactive Mtor Signalling

Mtorc1-Driven Tumor Cells Are Highly Sensitive to Therapeutic Targeting by Antagonists of Oxidative Stress

Aberrant Mtor/Autophagy/Nurr1 Signaling Is Critical For Tsc-Associated Tumor Development

Tuberous Sclerosis Complex is Required for Tumor Maintenance in MYC‐driven Burkitt's Lymphoma

Xct Deficiency Induces Autophagy Via Endoplasmic Reticulum Stress Activated P38-Mitogen-activated Protein Kinase and Mtor in Sut Melanocytes

Tsc Tumour Suppressor Proteins Antagonize Amino-Acid–tor Signalling

Impaired autophagy due to constitutive mTOR activation sensitizes TSC2-null cells to cell death under stress.

mTOR/miR-142-3p/PRAS40 signaling cascade is critical for tuberous sclerosis complex-associated renal cystogenesis

Combined Targeting of Mtor and Akt Using Rapamycin and MK-2206 in the Treatment of Tuberous Sclerosis Complex

Perfect match: mTOR inhibitors and tuberous sclerosis complex

Tsc1 Deficiency-Mediated Mtor Hyperactivation in Vascular Endothelial Cells Causes Angiogenesis Defects and Embryonic Lethality

Upregulation of acid ceramidase contributes to tumor progression in tuberous sclerosis

Modulation of TSC-mTOR Signaling on Immune Cells in Immunity and Autoimmunity.

TFEB drives mTORC1 hyperactivation and kidney disease in Tuberous Sclerosis Complex